Notable regulatory developments and financing activities signal shifts within the biotech sector. Sarepta Therapeutics refinanced approximately $700 million in convertible notes and faces class action investor lawsuits related to its securities trading period. QuidelOrtho completed substantial debt refinancing to improve financial flexibility, and Calidi Biotherapeutics closed a $6.9 million public offering to support its pipeline. Congressional formation of the BIOTech Caucus aims to advance bipartisan policies for maintaining US biotechnology leadership amid growing international competition. These developments underscore ongoing strategic financial positioning and policy engagement across the biotech industry.